Fig. 1: ER+, HER2− (non-amplified) breast cancer patients whose tumors are MutL− have elevated RNA levels of HER2 and associate with significantly worse disease-specific survival.
From: Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
A Incidence of tumors with elevated HER2 RNA levels within MutL− and MutL+ ER+/HER2− breast tumors from METABRIC (p = 0.0006) and TCGA. Pearson Chi-Square test identified p values. Corresponding RPPA data in Fig. S2A and contextualization with HER2+ subset in Fig. S2B, C. Kaplan–Meier survival curves (B) and proportional hazard assessment (C) demonstrating differences in disease-specific survival between specified groups within the ER+/HER2− breast tumor cohort from METABRIC. Boxes in (C) indicate the hazard ratio calculated using the Cox Proportional Hazards Regression analysis and error bars indicate the 95% confidence interval. Stage I p value = 0.0003. Supporting data from TCGA presented in Fig. S2D and proliferation controls in Fig. S2E, F. All statistical tests were two-sided. Source data for this figure are available with paper.
